Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Influenza

  Free Subscription


Articles published in Antiviral Res

Retrieve available abstracts of 67 articles:
HTML format
Text format



Single Articles


    March 2017
  1. LEYVA-GRADO VH, Palese P
    Aerosol administration increases the efficacy of oseltamivir for the treatment of mice infected with influenza viruses.
    Antiviral Res. 2017;142:12-15.
    PubMed     Text format     Abstract available


    February 2017
  2. PENDZIALEK J, Roose K, Smet A, Schepens B, et al
    Bispecific T-Cell engaging antibody constructs targeting a universally conserved part of the viral M2 ectodomain cure and prevent influenza A virus infection.
    Antiviral Res. 2017 Feb 28. pii: S0166-3542(16)30618.
    PubMed     Text format     Abstract available


  3. GAO L, Han J, Si J, Wang J, et al
    Cryptoporic acid E from Cryptoporus volvatus inhibits influenza virus replication in vitro.
    Antiviral Res. 2017 Feb 20. pii: S0166-3542(16)30540.
    PubMed     Text format     Abstract available


  4. COLEMAN BL, Hassan K, Green K, Gubbay JB, et al
    Pre-and post-pandemic trends in antiviral use in hospitalized patients with laboratory-confirmed influenza: 2004/05-2013/14, Toronto, Canada.
    Antiviral Res. 2017 Feb 5. pii: S0166-3542(16)30612.
    PubMed     Text format     Abstract available


  5. TAO W, Hurst B, Shakya AK, Uddin MJ, et al
    Consensus M2e peptide conjugated to gold nanoparticles confers protection against H1N1, H3N2 and H5N1 influenza A viruses.
    Antiviral Res. 2017 Feb 1. pii: S0166-3542(16)30409.
    PubMed     Text format     Abstract available


    January 2017
  6. HU Y, Musharrafieh R, Ma C, Zhang J, et al
    An M2-V27A channel blocker demonstrates potent in vitro and in vivo antiviral activities against amantadine-sensitive and -resistant influenza A viruses.
    Antiviral Res. 2017 Jan 10. pii: S0166-3542(16)30522.
    PubMed     Text format     Abstract available


    December 2016
  7. KOBAYASHI M, Kodama M, Noshi T, Yoshida R, et al
    Therapeutic efficacy of peramivir against H5N1 highly pathogenic avian influenza viruses harboring the neuraminidase H275Y mutation.
    Antiviral Res. 2016 Dec 21. pii: S0166-3542(16)30327.
    PubMed     Text format     Abstract available


    November 2016
  8. YANG WT, Yang GL, Wang Q, Huang HB, et al
    Protective efficacy of Fc targeting conserved influenza virus M2e antigen expressed by Lactobacillus plantarum.
    Antiviral Res. 2016 Nov 28. pii: S0166-3542(16)30462.
    PubMed     Text format     Abstract available


  9. YUAN S, Chu H, Ye J, Singh K, et al
    Identification of a novel small-molecule compound targeting the influenza A virus polymerase PB1-PB2 interface.
    Antiviral Res. 2016 Nov 10. pii: S0166-3542(16)30372.
    PubMed     Text format     Abstract available


  10. TU V, Abed Y, Barbeau X, Carbonneau J, et al
    The I427T neuraminidase (NA) substitution, located outside the NA active site of an influenza A(H1N1)pdm09 variant with reduced susceptibility to NA inhibitors, alters NA properties and impairs viral fitness.
    Antiviral Res. 2016;137:6-13.
    PubMed     Text format     Abstract available


    October 2016
  11. SMEE DF, Barnard DL, Jones SM
    Activities of JNJ63623872 and oseltamivir against influenza A H1N1pdm and H3N2 virus infections in mice.
    Antiviral Res. 2016 Oct 19. pii: S0166-3542(16)30404.
    PubMed     Text format     Abstract available


  12. WILSON JR, Guo Z, Reber A, Kamal RP, et al
    An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.
    Antiviral Res. 2016 Oct 3. pii: S0166-3542(16)30341.
    PubMed     Text format     Abstract available


    August 2016
  13. YATES PJ, Raimonde DS, Zhao HH, Man CY, et al
    Phenotypic and genotypic analysis of influenza viruses isolated from adult subjects during a phase II study of intravenous zanamivir in hospitalised subjects.
    Antiviral Res. 2016 Aug 25. pii: S0166-3542(16)30463.
    PubMed     Text format     Abstract available


  14. JANG Y, Lee HW, Shin JS, Go YY, et al
    Antiviral activity of KR-23502 targeting nuclear export of influenza B virus ribonucleoproteins.
    Antiviral Res. 2016 Aug 23. pii: S0166-3542(16)30206.
    PubMed     Text format     Abstract available


  15. LEMESSURIER KS, Lin Y, McCullers JA, Samarasinghe AE, et al
    Antimicrobial peptides alter early immune response to influenza A virus infection in C57BL/6 mice.
    Antiviral Res. 2016 Aug 13. pii: S0166-3542(16)30296.
    PubMed     Text format     Abstract available


  16. VOLLMER AH, Gebre MS, Barnard DL
    Serum amyloid A (SAA) is an early biomarker of influenza virus disease in BALB/c, C57BL/2, Swiss-Webster, and DBA.2 mice.
    Antiviral Res. 2016 Aug 11. pii: S0166-3542(16)30131.
    PubMed     Text format     Abstract available


  17. PIETRZAK M, Maciola A, Zdanowski K, Protas-Kulkowska AM, et al
    An avian influenza H5N1 virus vaccine candidate based on the extracellular domain produced in yeast system as subviral particles protects chickens from lethal challenge.
    Antiviral Res. 2016 Aug 3. pii: S0166-3542(16)30215.
    PubMed     Text format     Abstract available


  18. LIU WC, Liu YY, Chen TH, Liu CC, et al
    Multi-subtype influenza virus-like particles incorporated with flagellin and granulocyte-macrophage colony-stimulating factor for vaccine design.
    Antiviral Res. 2016;133:110-118.
    PubMed     Text format     Abstract available


    July 2016
  19. MA C, Li F, Musharrafieh R, Wang J, et al
    Discovery of cyclosporine A and its analogs as broad-spectrum anti-influenza drugs with a high in vitro genetic barrier of drug resistance.
    Antiviral Res. 2016 Jul 28. pii: S0166-3542(16)30148.
    PubMed     Text format     Abstract available


  20. CAI W, Chen S, Li Y, Zhang A, et al
    14-deoxy-11,12-didehydroandrographolide attenuates excessive inflammatory responses and protects mice lethally challenged with highly pathogenic A(H5N1) influenza viruses.
    Antiviral Res. 2016 Jul 27. pii: S0166-3542(16)30072.
    PubMed     Text format     Abstract available


  21. FU Y, Gaelings L, Soderholm S, Belanov S, et al
    JNJ872 inhibits influenza A virus replication without altering cellular antiviral responses.
    Antiviral Res. 2016;133:23-31.
    PubMed     Text format     Abstract available


  22. DAWOOD FS, Jara J, Gonzalez R, Castillo JM, et al
    A randomized, double-blind, placebo-controlled trial evaluating the safety of early oseltamivir treatment among children 0-9 years of age hospitalized with influenza in El Salvador and Panama.
    Antiviral Res. 2016 Jul 20. pii: S0166-3542(16)30221.
    PubMed     Text format     Abstract available


    June 2016
  23. TAKASHITA E, Ejima M, Ogawa R, Fujisaki S, et al
    Antiviral susceptibility of influenza viruses isolated from patients pre- and post-administration of favipiravir.
    Antiviral Res. 2016 Jun 16. pii: S0166-3542(16)30338.
    PubMed     Text format     Abstract available


  24. HURT AC, Besselaar TG, Daniels RS, Ermetal B, et al
    Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014-2015.
    Antiviral Res. 2016 Jun 2. pii: S0166-3542(16)30216.
    PubMed     Text format     Abstract available


    May 2016
  25. ALJURAYYAN AN, Sharma R, Upile N, Beer H, et al
    A critical role of T follicular helper cells in human mucosal anti-influenza response that can be enhanced by immunological adjuvant CpG-DNA.
    Antiviral Res. 2016 May 28. pii: S0166-3542(16)30129.
    PubMed     Text format     Abstract available


  26. ABED Y, Bouhy X, L'Huillier AG, Rheaume C, et al
    The E119D neuraminidase mutation identified in a multidrug-resistant influenza A(H1N1)pdm09 isolate severely alters viral fitness in vitro and in animal models.
    Antiviral Res. 2016 May 13. pii: S0166-3542(16)30161.
    PubMed     Text format     Abstract available


    February 2016
  27. YAMADA H, Nagase S, Takahashi K, Sakoda Y, et al
    Toll-like receptor 9 ligand D-type oligodeoxynucleotide D35 as a broad inhibitor for influenza A virus replication that is associated with suppression of neuraminidase activity.
    Antiviral Res. 2016 Feb 25. pii: S0166-3542(16)30089.
    PubMed     Text format     Abstract available


  28. CHERTOW DS, Kindrachuk J, Sheng ZM, Pujanauski LM, et al
    Influenza A and Methicillin-resistant Staphylococcus aureus Co-infection in Rhesus Macaques -- A Model of Severe Pneumonia.
    Antiviral Res. 2016 Feb 25. pii: S0166-3542(16)30098.
    PubMed     Text format     Abstract available


  29. MCKIMM-BRESCHKIN JL, Fry A
    Meeting report: 4 ISIRVAntiviral Group Conference: Novel Antiviral Therapies for Influenza and Other Respiratory Viruses.
    Antiviral Res. 2016 Feb 9. pii: S0166-3542(16)30015.
    PubMed     Text format     Abstract available


  30. SODERHOLM S, Anastasina M, Islam MM, Tynell J, et al
    Immuno-modulating properties of saliphenylhalamide, SNS-032, obatoclax, and gemcitabine.
    Antiviral Res. 2016;126:69-80.
    PubMed     Text format     Abstract available


  31. LYTRAS T, Kossyvakis A, Mentis A
    NAIplot: An opensource web tool to visualize neuraminidase inhibitor (NAI) phenotypic susceptibility results using kernel density plots.
    Antiviral Res. 2016;126:18-20.
    PubMed     Text format     Abstract available


  32. YANG JR, Chen CY, Kuo CY, Cheng CY, et al
    A novel H6N1 virus-like particle vaccine induces long-lasting cross-clade antibody immunity against human and avian H6N1 viruses.
    Antiviral Res. 2016;126:8-17.
    PubMed     Text format     Abstract available


    January 2016
  33. OKOMO-ADHIAMBO M, Mishin VP, Sleeman K, Saguar E, et al
    Standardizing the Influenza Neuraminidase Inhibition Assay among United States Public Health Laboratories Conducting Virological Surveillance.
    Antiviral Res. 2016 Jan 22. pii: S0166-3542(16)30011.
    PubMed     Text format     Abstract available


  34. YU J, Wang D, Jin J, Xu J, et al
    Antiviral activity of SA-2 against influenza A virus in vitro/vivo and its inhibition of RNA polymerase.
    Antiviral Res. 2016 Jan 20. pii: S0166-3542(16)30013.
    PubMed     Text format     Abstract available


  35. LIN C, Sun C, Liu X, Zhou Y, et al
    Design, synthesis, and in vitro biological evaluation of novel 6-methyl-7-substituted-7-deaza purine nucleoside analogs as anti-influenza A agents.
    Antiviral Res. 2016 Jan 20. pii: S0166-3542(16)30007.
    PubMed     Text format     Abstract available


  36. ZHOLOBAK NM, Mironenko AP, Shcherbakov AB, Shydlovska OA, et al
    Cerium dioxide nanoparticles increase immunogenicity of the influenza vaccine.
    Antiviral Res. 2016 Jan 5. pii: S0166-3542(15)30052.
    PubMed     Text format     Abstract available


  37. KIM Y, Kankanamalage AC, Damalanka VC, Weerawarna PM, et al
    Potent inhibition of enterovirus D68 and human rhinoviruses by dipeptidyl aldehydes and alpha-ketoamides.
    Antiviral Res. 2016;125:84-91.
    PubMed     Text format     Abstract available


  38. NORRIS MJ, Duan W, Cen Y, Moraes TJ, et al
    Agonistic 4-1BB antibody fails to reduce disease burden during acute respiratory syncytial virus (RSV) infection.
    Antiviral Res. 2016;125:46-50.
    PubMed     Text format     Abstract available


  39. GRANDIN C, Hourani ML, Janin YL, Dauzonne D, et al
    Respiratory syncytial virus infection in macaques is not suppressed by intranasal sprays of pyrimidine biosynthesis inhibitors.
    Antiviral Res. 2016;125:58-62.
    PubMed     Text format     Abstract available


    November 2015
  40. YUAN S, Chu H, Zhao H, Zhang K, et al
    Identification of a small-molecule inhibitor of influenza virus via disrupting the subunits interaction of the viral polymerase.
    Antiviral Res. 2015 Nov 21. pii: S0166-3542(15)30026.
    PubMed     Text format     Abstract available


    September 2015
  41. SHEPHARD A, Zybeshari S
    Virucidal action of sore throat lozenges against respiratory viruses parainfluenza type 3 and cytomegalovirus.
    Antiviral Res. 2015 Sep 22. pii: S0166-3542(15)00223.
    PubMed     Text format     Abstract available


  42. WEISS R, Laengle J, Sachet M, Shurygina AP, et al
    Interleukin-24 inhibits influenza A virus replication in vitro through induction of toll-like receptor 3 dependent apoptosis.
    Antiviral Res. 2015 Sep 11. pii: S0166-3542(15)00216.
    PubMed     Text format     Abstract available


  43. STRELTSOV VA, Pilling P, Barrett S, McKimm-Breschkin JL, et al
    Catalytic mechanism and novel receptor binding sites of human parainfluenza virus type 3 hemagglutinin-neuraminidase (hPIV3 HN).
    Antiviral Res. 2015 Sep 10. pii: S0166-3542(15)00209.
    PubMed     Text format     Abstract available


    August 2015
  44. LEE YN, Kim MC, Lee YT, Kim YJ, et al
    Co-immunization with tandem repeat heterologous M2 extracellular proteins overcomes strain-specific protection of split vaccine against influenza A virus.
    Antiviral Res. 2015 Aug 3. pii: S0166-3542(15)00174.
    PubMed     Text format     Abstract available


    June 2015
  45. YANG P, Li T, Liu N, Gu H, et al
    Recombinant influenza virus carrying human adenovirus epitopes elicits protective immunity in mice.
    Antiviral Res. 2015 Jun 23. pii: S0166-3542(15)00146.
    PubMed     Text format     Abstract available


  46. ZARUBAEV VV, Garshinina AV, Tretiak TS, Fedorova VA, et al
    Broad range of inhibiting action of novel camphor-based compound with anti-hemagglutinin activity against influenza viruses in vitro and in vivo.
    Antiviral Res. 2015 Jun 10. pii: S0166-3542(15)00135.
    PubMed     Text format     Abstract available


    May 2015
  47. PANOZZO J, Oh DY, Margo K, Morton DA, et al
    Evaluation of a dry powder delivery system for laninamivir in a ferret model of influenza infection.
    Antiviral Res. 2015;120:66-71.
    PubMed     Text format     Abstract available


  48. LIU R, An L, Liu G, Li X, et al
    Mouse lung slices: An ex vivo model for the evaluation of antiviral and anti-inflammatory agents against influenza viruses.
    Antiviral Res. 2015 May 26. pii: S0166-3542(15)00128.
    PubMed     Text format     Abstract available


  49. LU Y, Hardes K, Dahms SO, Bottcher-Friebertshauser E, et al
    Peptidomimetic furin inhibitor MI-701 in combination with oseltamivir and ribavirin efficiently blocks propagation of highly pathogenic avian influenza viruses and delays high level oseltamivir resistance in MDCK cells.
    Antiviral Res. 2015 May 25. pii: S0166-3542(15)00126.
    PubMed     Text format     Abstract available


  50. DABAGHIAN M, Latifi AM, Tebianian M, Dabaghian F, et al
    A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
    Antiviral Res. 2015 May 16. pii: S0166-3542(15)00111.
    PubMed     Text format     Abstract available


  51. STOPPANI E, Bassi I, Dotti S, Lizier M, et al
    Expression of a single siRNA against a conserved region of NP gene strongly inhibits in vitro replication of different Influenza A virus strains of avian and swine origin.
    Antiviral Res. 2015 May 16. pii: S0166-3542(15)00110.
    PubMed     Text format     Abstract available


    April 2015
  52. KIM S, Kim MJ, Park DY, Chung HJ, et al
    Mitochondrial reactive oxygen species modulate innate immune response to influenza A virus in human nasal epithelium.
    Antiviral Res. 2015 Apr 28. pii: S0166-3542(15)00103.
    PubMed     Text format     Abstract available


  53. HUI KP, Kuok DI, Kang SS, Li HS, et al
    Modulation of sterol biosynthesis regulates viral replication and cytokine production in influenza A virus infected human alveolar epithelial cells.
    Antiviral Res. 2015 Apr 13. pii: S0166-3542(15)00085.
    PubMed     Text format     Abstract available


    March 2015
  54. CAI W, Li Y, Chen S, Wang M, et al
    14-Deoxy-11,12-dehydroandrographolide exerts anti-influenza A virus activity and inhibits replication of H5N1 virus by restraining nuclear export of viral ribonucleoprotein complexes.
    Antiviral Res. 2015 Mar 20. pii: S0166-3542(15)00060.
    PubMed     Text format     Abstract available


  55. ONISHI M, Kitano M, Taniguchi K, Homma T, et al
    Intravenous peramivir inhibits viral replication, and leads to bacterial clearance and prevention of mortality during murine bacterial co-infection caused by influenza A(H1N1)pdm09 virus and Streptococcus pneumoniae.
    Antiviral Res. 2015 Mar 6. pii: S0166-3542(15)00051.
    PubMed     Text format     Abstract available


  56. SALLY DAVIS A, Taubenberger JK, Bray M
    The use of nonhuman primates in research on seasonal, pandemic and avian influenza, 1893-2014.
    Antiviral Res. 2015 Mar 5. pii: S0166-3542(15)00050.
    PubMed     Text format     Abstract available


    February 2015
  57. TAKASHITA E, Meijer A, Lackenby A, Gubareva L, et al
    Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2013-2014.
    Antiviral Res. 2015 Feb 23. pii: S0166-3542(15)00031.
    PubMed     Text format     Abstract available


  58. BARANOVICH T, Bahl J, Marathe BM, Culhane M, et al
    Influenza A viruses of swine circulating in the United States during 2009-2014 are susceptible to neuraminidase inhibitors but show lineage-dependent resistance to adamantanes.
    Antiviral Res. 2015 Feb 19. pii: S0166-3542(15)00032.
    PubMed     Text format     Abstract available


  59. BARNWAL B, Mok CK, Wu J, Diwakar MK, et al
    A monoclonal antibody binds to threonine 49 in the non-structural 1 protein of influenza A virus and interferes with its ability to modulate viral replication.
    Antiviral Res. 2015 Feb 6. pii: S0166-3542(15)00028.
    PubMed     Text format     Abstract available


    December 2014
  60. AHMED MS, Jacques LC, Mahallawi W, Ferrara F, et al
    Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.
    Antiviral Res. 2014 Dec 13. pii: S0166-3542(14)00359.
    PubMed     Text format     Abstract available


  61. LEE YN, Hwang HS, Kim MC, Lee YT, et al
    Recombinant Influenza Virus Expressing a Fusion Protein Neutralizing Epitope of Respiratory Syncytial Virus (RSV) Confers Protection without Vaccine-Enhanced RSV Disease.
    Antiviral Res. 2014 Dec 13. pii: S0166-3542(14)00360.
    PubMed     Text format     Abstract available


  62. ABED Y, Pizzorno A, Bouhy X, Boivin G, et al
    Permissive changes in the neuraminidase play a dominant role in improving the viral fitness of oseltamivir-resistant seasonal influenza A(H1N1) strains.
    Antiviral Res. 2014 Dec 12. pii: S0166-3542(14)00346.
    PubMed     Text format     Abstract available


    November 2014
  63. MATUSEVICH OV, Egorov VV, Gluzdikov IA, Titov MI, et al
    Synthesis and antiviral activity of PB1 component of the influenza A RNA polymerase peptide fragments.
    Antiviral Res. 2014;113C:4-10.
    PubMed     Text format     Abstract available


  64. ZHU HY, Han L, Shi XL, Wang BL, et al
    Baicalin inhibits autophagy induced by influenza A virus H3N2.
    Antiviral Res. 2014;113C:62-70.
    PubMed     Text format     Abstract available


    October 2014
  65. BABAR MM, Zaidi NU, Tahir M
    Global geno-proteomic analysis reveals cross-continental sequence conservation and druggable sites among influenza virus polymerases.
    Antiviral Res. 2014;112C:120-131.
    PubMed     Text format     Abstract available


    May 2014
  66. FU YH, Jiao YY, He JS, Giang GY, et al
    Sublingual administration of a helper-dependent adenoviral vector expressing the codon-optimized soluble fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in mice.
    Antiviral Res. 2014;105:72-9.
    PubMed     Text format     Abstract available


    April 2014
  67. KWON YM, Hwang HS, Lee JS, Ko EJ, et al
    Maternal antibodies by passive immunization with formalin inactivated respiratory syncytial virus confer protection without vaccine-enhanced disease.
    Antiviral Res. 2014;104:1-6.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: